Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions.
Falorio S, Biasoli I, Luminari S, Quintana G, Musso M, Dell'olio M, Specchia MR, di Renzo N, Cesaretti M, Buda G, Vallisa D, Mannina D, Andriani A, Chiattone CS, Delamain MT, de Souza CA, Spector N, Angrilli F, Federico M. Falorio S, et al. Among authors: buda g. Hematol Oncol. 2013 Jun;31(2):72-8. doi: 10.1002/hon.2029. Epub 2012 Oct 2. Hematol Oncol. 2013. PMID: 23027689
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S, Mancuso S, De Paolis MR, Plati C, Stelitano C, Patti C, Olivieri A, Liardo E, Buda G, Cantaffa R, Federico M. Di Renzo N, et al. Among authors: buda g. Support Care Cancer. 2011 Oct;19(10):1505-10. doi: 10.1007/s00520-010-0974-y. Epub 2010 Aug 8. Support Care Cancer. 2011. PMID: 20694798 Free PMC article. Clinical Trial.
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
Sacchi S, Marcheselli R, Bari A, Buda G, Molinari AL, Baldini L, Vallisa D, Cesaretti M, Musto P, Ronconi S, Specchia G, Silvestris F, Guardigni L, Ferrari A, Chiapella A, Carella AM, Santoro A, Di Raimondo F, Marcheselli L, Pozzi S. Sacchi S, et al. Among authors: buda g. Haematologica. 2016 May;101(5):e196-9. doi: 10.3324/haematol.2015.139329. Epub 2016 Feb 8. Haematologica. 2016. PMID: 26858355 Free PMC article. Clinical Trial. No abstract available.
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Bari A, Marcheselli R, Marcheselli L, Alvarez I, Pozzi S, Ferri P, Lazzaro A, Fragasso A, Neri S, Baldini L, Carella AM, Angrilli F, Guariglia R, Buda G, Stelitano C, Sacchi S; Gruppo Italiano Studio Linfomi (GISL). Bari A, et al. Among authors: buda g. Acta Haematol. 2017;137(1):7-14. doi: 10.1159/000449052. Epub 2016 Nov 4. Acta Haematol. 2017. PMID: 27820922 Clinical Trial.
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni Bezzi C, Scalese M, Dozza L, Marzocchi G, Martello M, Barilà G, Antonioli E, Staderini M, Buda G, Petrini M, Cea M, Quaresima M, Furlan A, Bonalumi A, Cavo M, Zamagni E. Rocchi S, et al. Among authors: buda g. Hematol Oncol. 2021 Feb;39(1):41-50. doi: 10.1002/hon.2820. Epub 2020 Nov 1. Hematol Oncol. 2021. PMID: 33085797 Clinical Trial.
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
Orciuolo E, Buda G, Marturano E, Mauro E, Milone G, Cangialosi C, Di Renzo N, Pastore D, Specchia G, De Paolis MR, Mazza P, Pietrantuono G, Petrini M. Orciuolo E, et al. Among authors: buda g. Leuk Res. 2011 Jul;35(7):899-903. doi: 10.1016/j.leukres.2010.10.029. Epub 2010 Dec 4. Leuk Res. 2011. PMID: 21134693 Free article. Clinical Trial.
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
Sacchi S, Marcheselli R, Lazzaro A, Morabito F, Fragasso A, Di Renzo N, Balleari E, Neri S, Quarta G, Ferrara R, Vigliotti ML, Polimeno G, Musto P, Consoli U, Zoboli A, Buda G, Pastorini A, Masini L. Sacchi S, et al. Among authors: buda g. Leuk Lymphoma. 2011 Oct;52(10):1942-8. doi: 10.3109/10428194.2011.584006. Epub 2011 Jun 12. Leuk Lymphoma. 2011. PMID: 21663513 Clinical Trial.
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study.
Del Giudice ML, Gozzetti A, Antonioli E, Orciuolo E, Ghio F, Ciofini S, Candi V, Fontanelli G, Attucci I, Formica G, Bocchia M, Galimberti S, Petrini M, Buda G. Del Giudice ML, et al. Among authors: buda g. Medicina (Kaunas). 2021 Aug 28;57(9):900. doi: 10.3390/medicina57090900. Medicina (Kaunas). 2021. PMID: 34577823 Free PMC article.
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.
Antonioli E, Pilerci S, Attucci I, Buda G, Gozzetti A, Candi V, Simonetti F, Giudice MLD, Ciofini S, Staderini M, Grammatico S, Buzzichelli A, Messeri M, Bocchia M, Galimberti S, Vannucchi AM. Antonioli E, et al. Among authors: buda g. Front Oncol. 2023 Apr 25;13:1162990. doi: 10.3389/fonc.2023.1162990. eCollection 2023. Front Oncol. 2023. PMID: 37182182 Free PMC article.
158 results